These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26667261)

  • 1. Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples.
    Smith SL; Eyre S; Yarwood A; Hyrich K; Morgan AW; Wilson AG; Isaacs J; ; Plant D; Barton A
    Arthritis Res Ther; 2015 Dec; 17():359. PubMed ID: 26667261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.
    Stuhlmüller B; Häupl T; Hernandez MM; Grützkau A; Kuban RJ; Tandon N; Voss JW; Salfeld J; Kinne RW; Burmester GR
    Clin Pharmacol Ther; 2010 Mar; 87(3):311-21. PubMed ID: 20032971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
    Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
    BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
    Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
    Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis.
    Thomson TM; Lescarbeau RM; Drubin DA; Laifenfeld D; de Graaf D; Fryburg DA; Littman B; Deehan R; Van Hooser A
    BMC Med Genomics; 2015 Jun; 8():26. PubMed ID: 26036272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.
    Tweehuysen L; Schraa K; Netea MG; van den Hoogen FHJ; Joosten LAB; den Broeder AA
    Clin Exp Rheumatol; 2018; 36(1):140-143. PubMed ID: 29148425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
    Cuppen BV; Rossato M; Fritsch-Stork RD; Concepcion AN; Schenk Y; Bijlsma JW; Radstake TR; Lafeber FP;
    Arthritis Res Ther; 2016 Aug; 18(1):189. PubMed ID: 27558398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.
    Oliver J; Nair N; Orozco G; Smith S; Hyrich KL; Morgan A; Isaacs J; Wilson AG; ; Barton A; Plant D
    Arthritis Res Ther; 2021 Mar; 23(1):80. PubMed ID: 33691749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
    Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.
    Oswald M; Curran ME; Lamberth SL; Townsend RM; Hamilton JD; Chernoff DN; Carulli J; Townsend MJ; Weinblatt ME; Kern M; Pond CM; Lee A; Gregersen PK
    Arthritis Rheumatol; 2015 Feb; 67(2):344-51. PubMed ID: 25371395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis.
    Nguyen MVC; Baillet A; Romand X; Trocmé C; Courtier A; Marotte H; Thomas T; Soubrier M; Miossec P; Tébib J; Grange L; Toussaint B; Lequerré T; Vittecoq O; Gaudin P
    Joint Bone Spine; 2019 Mar; 86(2):195-201. PubMed ID: 29885551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Impact of Biologic Therapy on Heart Function Biomarkers in Rheumatoid Arthritis Patients: Observational Study on Etanercept, Adalimumab, and Tocilizumab.
    Dubiel-Braszczok B; Nowak K; Owczarek A; Engelmann M; Gumkowska-Sroka O; Kotyla PJ
    Curr Pharm Des; 2022; 28(24):2029-2037. PubMed ID: 35638285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation.
    Lin YC; Lin YC; Wu CC; Huang MY; Tsai WC; Hung CH; Kuo PL
    Oncotarget; 2017 Jan; 8(5):7559-7571. PubMed ID: 27926504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability.
    Navarro-Millán I; Herrinton LJ; Chen L; Harrold L; Liu L; Curtis JR
    PLoS One; 2016; 11(3):e0149781. PubMed ID: 27007811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis.
    L' Ami MJ; Ruwaard J; Krieckaert C; Nurmohamed MT; van Vollenhoven RF; Rispens T; Wolbink GJ
    Scand J Rheumatol; 2019 Jul; 48(4):266-270. PubMed ID: 31012365
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.